<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400686</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-5497</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-5497</secondary_id>
    <secondary_id>ORTHO-CASE-CCF-5497</secondary_id>
    <nct_id>NCT00400686</nct_id>
  </id_info>
  <brief_title>Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma</brief_title>
  <official_title>A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat&#xD;
      anemia in patients with multiple myeloma.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well epoetin alfa works in treating anemia in&#xD;
      patients undergoing chemotherapy for multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the hematologic response and transfusion requirements of chemotherapy-related&#xD;
           moderate anemia to the administration of a high initial dose of epoetin alfa followed by&#xD;
           a less frequent maintenance dose of epoetin alfa in multiple myeloma patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the effect of moderate anemia on quality of life in these patients.&#xD;
&#xD;
        -  Correlate changes in hemoglobin levels with changes in quality of life in patients&#xD;
           treated with this drug.&#xD;
&#xD;
        -  Determine the effect of this drug on transfusion requirements after day 28 in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, pilot study.&#xD;
&#xD;
      Patients receive high-dose epoetin alfa subcutaneously (SC) once a week for 4 weeks or until&#xD;
      their hemoglobin levels reach 12-13 g/dL. Patients then receive epoetin alfa SC once every 2&#xD;
      weeks for 8 weeks OR once a week for 4 weeks, and then once every 2 weeks for 8 weeks (as&#xD;
      long as their hemoglobin levels remain between 12-13 g/dL). Patients then receive maintenance&#xD;
      epoetin alfa SC once every 4 weeks for up to 12 weeks.&#xD;
&#xD;
      Patients whose hemoglobin level decreases by 1-1.5 g/dL return to previous epoetin alfa&#xD;
      schedule. Patients whose hemoglobin level is &lt; 9 g/dL after returning to the previous&#xD;
      schedule may receive epoetin alfa for an additional 24 weeks.&#xD;
&#xD;
      Quality of life is assessed at baseline and at weeks 2, 4, 8, 16, and 24 weeks during&#xD;
      treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin at Day 28</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Change from baseline in hemoglobin after treatment with high-dose Epoetin Alfa.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With an at Least 1gm/dL Increase in Hgb</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With an at Least 2gm/dL Increase in Hgb</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Anemia</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Epoetin Alfa - 80,000 U sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>epoetin alfa</intervention_name>
    <description>Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
    <arm_group_label>Epoetin Alfa - 80,000 U sc</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma (MM)&#xD;
&#xD;
          -  Requiring active therapy for MM&#xD;
&#xD;
               -  Planning to undergo chemotherapy for ≥ 3 months&#xD;
&#xD;
          -  Moderate anemia caused by MM and/or chemotherapy, as evidenced by hemoglobin ≤ 11.0&#xD;
             g/dL&#xD;
&#xD;
          -  No untreated anemia predominantly due to factors other than MM/chemotherapy (i.e.,&#xD;
             iron or folate deficiencies, hemolysis, HIV, or gastrointestinal bleeding)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Transferrin saturation ≥ 20%&#xD;
&#xD;
          -  Ferritin ≥ 100 ng/mL&#xD;
&#xD;
          -  Homocysteine normal (concurrent vitamin supplementation allowed)&#xD;
&#xD;
          -  Methylmalonic acid normal (concurrent vitamin supplementation allowed)&#xD;
&#xD;
          -  Renal function normal&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No prior thrombotic events unless treated with appropriate prophylaxis&#xD;
&#xD;
          -  No known hypersensitivity to mammalian cell-derived products&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell skin cancer or carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Weight &lt; 100 Kg&#xD;
&#xD;
          -  Patients with iron, folate, or vitamin B_12 deficiency allowed provided conditions are&#xD;
             corrected prior to study entry&#xD;
&#xD;
          -  Able to read and understand English at a 7th grade level&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior total lymphoid, extensive abdominal, or inverted Y radiotherapy&#xD;
&#xD;
          -  Concurrent red blood cell transfusion allowed provided hemoglobin ≤ 7 g/dL AND patient&#xD;
             is symptomatic&#xD;
&#xD;
          -  Concurrent vitamin supplementation allowed for cyanocobalamin (vitamin B_12) or folate&#xD;
             deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M. Sobecks, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <results_first_submitted>June 3, 2015</results_first_submitted>
  <results_first_submitted_qc>October 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2016</results_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From 9/2003 to 6/2008, a total of 31 patients were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Epoetin Alfa - 80,000 U sc</title>
          <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels&#xD;
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Epoetin Alfa - 80,000 U sc</title>
          <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels&#xD;
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" lower_limit="41" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin at Day 28</title>
        <description>Change from baseline in hemoglobin after treatment with high-dose Epoetin Alfa.</description>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 80,000 U sc</title>
            <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels&#xD;
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin at Day 28</title>
          <description>Change from baseline in hemoglobin after treatment with high-dose Epoetin Alfa.</description>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-3.0" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With an at Least 1gm/dL Increase in Hgb</title>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 80,000 U sc</title>
            <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels&#xD;
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an at Least 1gm/dL Increase in Hgb</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With an at Least 2gm/dL Increase in Hgb</title>
        <time_frame>Baseline to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa - 80,000 U sc</title>
            <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels&#xD;
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With an at Least 2gm/dL Increase in Hgb</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data highlights development of VTEs in patients receiving one of the following: 1. lenalidomide, high dose dexamethasone &amp; Aspirin 325mg daily 2. thalidomide &amp; doxil based therapy with aspirin 81mg daily 3. cyclophosphamide &amp; prednisone without VTE</time_frame>
      <desc>Only immediately reportable Serious Adverse Events (SAE) &amp; Venous thrombolytic event (VTE) were captured for the purpose of this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Epoetin Alfa - 80,000 U sc</title>
          <description>Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels&#xD;
epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Venous Thromboembolic Event (VTE)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Beth Faiman, MSN,CNP, AOCN</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-3738</phone>
      <email>faimanb@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

